Abciximab plus stenting reduced coronary events in patients with acute myocardial infarction

Kitching, Allan D.; Weiss, Robert
May 2002
ACP Journal Club;May/Jun2002, Vol. 136 Issue 3, p89
Academic Journal
Comments on a study which examined the use of platelet glycoprotein IIb/IIIa iInhibition with coronary stenting for acute myocardial infarction. Outcome measures; Effect of platelet glycoprotein IIb/IIIa inhibitors on patients having elective percutaneous coronary intervention; Benefits from abciximab or placebo.


Related Articles

  • Improving reperfusion after myocardial infarction. Menown, Ian B. A.; Adgey, A. A. Jennifer // BMJ: British Medical Journal (International Edition);12/11/99, Vol. 319 Issue 7224, p1513 

    Editorial. Discusses the use of glycoprotein IIb/IIIa antagonists as adjuncts to fibrinolytic therapy for acute myocardial infarction. Activation of platelets through agonists; Benefits of combining abciximab with alteplase; Details on how to prevent reocclusion.

  • Rise and fall of glycoprotein IIb-IIIa inhibitors in ST-segment elevation myocardial infarction. Di Mario, Carlo // Heart;Jun2014, Vol. 100 Issue 11, p823 

    The article reflects on a study titled "Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI)" by researcher J.J. Russo and others. It mentions that the study included angioplasty, fibrinolytic therapy, and evaluation of...

  • Thrombus management in the catheterisation laboratory in the setting of primary percutaneous coronary intervention: what is the current evidence? Dharma, Surya; Kedev, Sasko; Jukema, J Wouter // Heart;Feb2013, Vol. 99 Issue 4, p279 

    The article discusses a study related to the effectiveness of primary percutaneous coronary intervention (PPCI) in the treatment of acute ST elevation myocardial infarction (STEMI). It informs that acute reperfusion parameters during PPCI are necessary for immediate evaluation of the success of...

  • Glycoprotein IIb/IIIa Inhibitor (Tirofiban) in Acute ST-Segment Elevation Myocardial Infarction. Ching-Chang Fang; Yeun Tarl Fresner Ng Jao; Yi Chen; Ching-Lung Yu; Shih-Pu Wang // Angiology;Apr/May2009, Vol. 60 Issue 2, p192 

    Studies have shown conflicting results for glycoprotein IIb/IIIa inhibitor (tirofiban) use in ST-segment elevation myocardial infarction (STEMI). The authors aimed to determine if an upstream conventional dose of tirofiban in addition to a standard treatment regimen improved coronary patency and...

  • Some of the best medicines are all in the mind. Motluk, Alison // New Scientist;8/18/2001, Vol. 171 Issue 2304, p19 

    Reports on the positive effect of placebos on health. Details of a study conducted on patients with Parkinson's disease using either a placebo or apomorphine drug.

  • Is there a place for placebo controlled trials of antiepileptic drugs? Shorvon, S.D.; Espir, M.L.E.; Steiner, T.J.; Dellaportas, C.I.; Rose, F. Clifford // British Medical Journal (Clinical Research Edition);11/9/1985, Vol. 291 Issue 6505, p1328 

    Examines the possibility of a placebo controlled trials on antiepileptic drugs in Great Britain. Uncertainty on the role of anticonvulsant drugs on epileptics; Impact of epileptic seizures on the psychology and social behavior of epileptics; Natural history of epilepsy.

  • Relief of Idiopathic Generalized Pruritus in Dialysis Patients Treated with Activated Oral Charcoal. Pederson, James A.; Matter, Billy J.; Czerwinski, Anthony W.; Llach, Francisco // Annals of Internal Medicine;Sep80, Vol. 93 Issue 3, p446 

    Presents information on a study which compared the effect of oral charcoal on idiopathic generalized pruritus in stable patients undergoing maintenance hemodialysis to that of placebo dextrose. Results of skin tests; Effect of charcoal and placebo treatment upon the skin lesions; Discussion on...

  • Hypnotic self administration: forced-choice versus single-choice. Roehrs, T.; Pedrosi, Bonita; Rosenthal, Leon; Zorick, Frank; Roth, Thomas // Psychopharmacology;1997, Vol. 133 Issue 2, p121 

    Abstract Twenty-four men and women with insomnia, age 21-50 years, self administered hypnotics under a single-choice with placebo, single-choice with triazolam (0.25 mg), or forced-choice of placebo versus triazolam (0.25mg) paradigm. Subjects received 4- sampling nights of placebo or triazolam...

  • Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. Jolley, A.G.; Hirsch, S.R.; McRink, A.; Manchanda, R. // BMJ: British Medical Journal (International Edition);4/15/89, Vol. 298 Issue 6679, p985 

    Evaluates the trial of intermittent neuroleptic prophylaxis for schizophrenic outpatients in Great Britain. Approach to prophylaxis of schizophrenic relapse; Outline of the treatment strategy; Administration of placebo injections.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics